Description
Paxlovid – Oral Antiviral Treatment for COVID-19
Paxlovid is a combination of two oral antiviral medicines: Nirmatrelvir (150 mg) and Ritonavir (100 mg). It is FDA-authorized for the treatment of mild-to-moderate COVID-19 in patients who are at high risk of progressing to severe illness. Paxlovid helps reduce viral load and prevents hospitalization when started early.
Key Benefits:
- Proven to reduce risk of severe COVID-19 or hospitalization
- Oral treatment – no injections required
- Effective against multiple COVID-19 variants
- Well-tolerated with a 5-day treatment course
- Authorized by FDA, WHO, and other regulatory bodies
How to Use:
The standard dosage is two tablets of Nirmatrelvir (150 mg each) + one tablet of Ritonavir (100 mg) taken together, twice daily for 5 days. Begin treatment within 5 days of symptom onset. Do not skip doses or discontinue early without medical advice.
Precautions:
- Do not use without a valid prescription
- Not recommended for patients with severe liver or kidney issues
- May interact with other medications – inform your doctor of all current treatments
- Consult your doctor if pregnant, breastfeeding, or immunocompromised
Storage Instructions:
Store below 25°C in a dry place, in the original blister packaging. Keep out of reach of children.
Frequently Asked Questions (FAQs)
1. What is Paxlovid used for?
It is used to treat mild-to-moderate COVID-19 in people who are at high risk for progression to severe illness, hospitalization, or death.
2. How soon should I start Paxlovid?
It should be started within 5 days of symptom onset for maximum effectiveness. Early initiation is critical.
3. How long is the treatment course?
The full course lasts 5 days, with doses taken twice daily. Do not stop early even if you start feeling better.
4. Are there side effects?
Common side effects include altered taste, diarrhea, high blood pressure, and muscle pain. Always report any unusual reactions to your doctor.
5. Can Paxlovid prevent COVID-19?
No. Paxlovid is not for prevention or post-exposure prophylaxis. It is only for active infections with a positive COVID-19 test.
6. Is it effective against new variants?
Yes. Paxlovid has been shown to retain activity against several variants, including Omicron. Efficacy may vary as the virus evolves, so follow current guidance.
Reviews
There are no reviews yet.